PharmaCyte Biotech, Inc.

PharmaCyte Biotech, Inc. These encapsulated cells are implanted as close to the patient’s cancerous tumor as possible. https://goo.gl/Gc6CvW

PharmaCyte Biotech (NASDAQ: PMCB) is a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®. PharmaCyte Biotech a clinical stage biotechnology company developing therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed. PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide comes in contact with the encapsulated cells they act as an artificial liver and activate the chemotherapy drug at the source of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in no side effects. In addition to developing a novel therapy for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and insulin-dependent Type 2 diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology. Once the encapsulated cells are implanted in a diabetic patient they will function as a “bio-artificial pancreas” for purposes of insulin production. Please follow our social community guidelines while commenting and posting on this page.

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois CapitalCompany Appoints Five New Independent Directors to...
08/15/2022

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

Company Appoints Five New Independent Directors to Reconstituted Board

PharmaCyte and Iroquois have reached a settlement which includes appointing five new independent directors to PharmaCyte's reconstituted Board.

PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation
07/28/2022

PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study
07/21/2022

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study
07/19/2022

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malignant ascites

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022
07/11/2022

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

Preliminary Financial Results for Fiscal Year 2022 are announced by PharmaCyte Biotech, Inc.

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells
07/05/2022

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites u

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to ...
06/15/2022

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malign

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego
06/13/2022

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes and malign

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Val...
06/08/2022

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

PharmaCyte Biotech, Inc. (NASDAQ: PMCB) (PharmaCyte), a biotechnology company focused on developing cellular therapies for cancer, diabetes, and malig

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program
06/02/2022

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

PharmaCyte has authorized a share repurchase program to repurchase up to $10 million of PharmaCyte’s outstanding common stock.

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites
05/23/2022

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature

PharmaCyte Biotech to Attend 15th National Conference on Advanced Technologies and Treatments
04/27/2022

PharmaCyte Biotech to Attend 15th National Conference on Advanced Technologies and Treatments

PharmaCyte's management team is attending the 15th International Conference on Advanced Technologies and Treatment for Diabetes in Barcelona, Spain.

Address

3960 Howard Hughes Parkway, Suite 500
Las Vegas, NV
89169

Website

Alerts

Be the first to know and let us send you an email when PharmaCyte Biotech, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to PharmaCyte Biotech, Inc.:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company developing cellular therapies for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This technology will be used as a platform upon which therapies for several types of cancer and diabetes are being developed.

PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form. For pancreatic cancer, these encapsulated cells are implanted in the blood supply to the patient’s tumor as close as possible to the site of the tumor. Once implanted, a chemotherapy drug that is normally activated in the liver (ifosfamide) is given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been implanted. When the ifosfamide flows through pores in the capsules, the live cells inside act as a “bio-artificial liver” and activate the chemotherapy drug at the site of the cancer. This “targeted chemotherapy” has proven effective and safe to use in past clinical trials and results in little to no treatment related side effects.

PharmaCyte’s therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes involves encapsulating a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. PharmaCyte is exploring the use of genetically modified liver cells, stem cells and/or beta islet cells. The encapsulation will be done using the Cell-in-a-Box®technology. Once the encapsulated cells are implanted in a diabetic patient, they will function as a “bio-artificial pancreas” for purposes of insulin production.